Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Docetaxel in Hormone Refractory Metastatic Prostate Cancer
NCT00003781Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Dec 1998
- Primary completion
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in prostate cancer (PCa), sponsored by OHSU Knight Cancer Institute. Primary endpoints: Disease Response, Strength and Duration of Pain Reduction and 2 more. Started Dec 1998; status: completed.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00003781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003781.